News Image

For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.

By Mill Chart

Last update: Mar 26, 2024

Take a closer look at INCYTE CORP (NASDAQ:INCY), a remarkable value stock uncovered by our stock screener. NASDAQ:INCY excels in fundamentals and maintains a very reasonable valuation. Let's break it down further.

Unpacking NASDAQ:INCY's Valuation Rating

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:INCY has achieved a 8 out of 10:

  • INCY's Price/Earnings ratio is rather cheap when compared to the industry. INCY is cheaper than 97.28% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.09, INCY is valued a bit cheaper.
  • 97.96% of the companies in the same industry are more expensive than INCY, based on the Price/Forward Earnings ratio.
  • INCY's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.45.
  • Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaper than 96.94% of the companies in the same industry.
  • INCY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INCY is cheaper than 96.09% of the companies in the same industry.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • INCY has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as INCY's earnings are expected to grow with 25.08% in the coming years.

Analyzing Profitability Metrics

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NASDAQ:INCY scores a 8 out of 10:

  • INCY's Return On Assets of 8.81% is amongst the best of the industry. INCY outperforms 96.94% of its industry peers.
  • INCY has a Return On Equity of 11.51%. This is amongst the best in the industry. INCY outperforms 96.60% of its industry peers.
  • INCY has a Return On Invested Capital of 8.00%. This is amongst the best in the industry. INCY outperforms 96.43% of its industry peers.
  • INCY has a better Profit Margin (16.17%) than 97.11% of its industry peers.
  • In the last couple of years the Profit Margin of INCY has grown nicely.
  • The Operating Margin of INCY (17.64%) is better than 96.77% of its industry peers.
  • INCY's Operating Margin has improved in the last couple of years.
  • The Gross Margin of INCY (93.71%) is better than 95.24% of its industry peers.

Deciphering NASDAQ:INCY's Health Rating

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:INCY has earned a 7 out of 10:

  • An Altman-Z score of 6.36 indicates that INCY is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 6.36, INCY is doing good in the industry, outperforming 79.93% of the companies in the same industry.
  • The Debt to FCF ratio of INCY is 0.07, which is an excellent value as it means it would take INCY, only 0.07 years of fcf income to pay off all of its debts.
  • INCY has a better Debt to FCF ratio (0.07) than 97.62% of its industry peers.
  • INCY has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • INCY has a Current Ratio of 3.75. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
  • INCY has a Quick Ratio of 3.69. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.

Deciphering NASDAQ:INCY's Growth Rating

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:INCY was assigned a score of 7 for growth:

  • The Earnings Per Share has grown by an impressive 26.62% over the past year.
  • INCY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 27.86% yearly.
  • The Revenue has grown by 8.87% in the past year. This is quite good.
  • The Revenue has been growing by 14.45% on average over the past years. This is quite good.
  • The Earnings Per Share is expected to grow by 18.66% on average over the next years. This is quite good.
  • Based on estimates for the next years, INCY will show a quite strong growth in Revenue. The Revenue will grow by 8.13% on average per year.

More Decent Value stocks can be found in our Decent Value screener.

Our latest full fundamental report of INCY contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

INCYTE CORP

NASDAQ:INCY (4/18/2024, 7:01:07 PM)

After market: 52.82 0 (0%)

52.82

+0.1 (+0.19%)

INCY News

News Image13 hours ago - Market News VideoEquitable Holdings Larger Than S&P 500 Component Incyte
News Image2 days ago - ChartmillWhen you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.

News Image4 days ago - ChartmillDiscover the top S&P500 movers in Monday's pre-market session and stay informed about market dynamics.

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.

News Image7 days ago - Market News VideoIncyte Enters Oversold Territory (INCY)
News Image8 days ago - IncyteIncyte to Report First Quarter Financial Results
News Image14 days ago - ChartmillNASDAQ:INCY stands out as a growth opportunity that won't break the bank.

NASDAQ:INCY is showing good growth, while it is not too expensive.

News Image18 days ago - IncyteIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
News Image21 days ago - IncyteIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Imagea month ago - Market News VideoFirst Week of May 17th Options Trading For Incyte (INCY)
News Imagea month ago - InvestorPlacePenny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead

Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.

News Imagea month ago - IncyteIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
News Imagea month ago - Incyte CorporationIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
INCY Links
Follow us for more